This review discusses the potential association between vaccination and alopecia areata, highlighted in case reports, notably with the hepatitis B virus vaccine, but provides no new results.
1 citations
,
June 2001 in “Annals of Internal Medicine” This letter critiques a review of distant healing studies, highlighting significant methodological issues and limited evidence for its efficacy.
1 citations
,
December 2004 in “Hepatology” This study found that in lamivudine-resistant hepatitis B patients, tenofovir significantly reduced HBV DNA levels faster and more consistently than adefovir, reaching undetectable levels in all treated patients by 44 weeks.
23 citations
,
January 2009 in “Veterinary Dermatology” This study found that recombinant hepatitis B vaccine may increase the risk of alopecia areata onset in older predisposed mice but larger trials suggest this effect might lie within normal variation.
176 citations
,
June 2016 in “PLoS ONE” In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.